A
Avelos Therapeutics
Develops next-generation targeted oncology medicines with high unmet need, to a wider range of possibilities with present and future applications
About Avelos Therapeutics
Avelos Therapeutics, a South Korean biotechnology firm established on September 1, 2021, is focused on the research and development of anti-cancer therapies. The company was founded by a team of experts in new drug development: CEO Young-Whan Park, CTO Soongyu Choi (promoted to co-CEO in January 2024), and Head of Business Development Kangsik Yun. Dr. Park previously led National OncoVenture (NOV), a Korean government-funded anti-cancer drug development program, and worked as a program leader at Merck & Co. in the US. Soongyu Choi has experience leading pharmaceutical companies like Bayer Healthcare and PTC Therapeutics, while Kangsik Yun has over 30 years of experience in drug discovery and development.
The company operates in the oncology market, developing biomarker-driven, targeted therapies for cancer treatment. Its business revolves around discovering and developing small molecule drugs that target areas previously considered "undruggable," such as cell cycle regulation and DNA damage response. Avelos Therapeutics' core technology is a proprietary platform named "SMILO" (Small Molecules Inducing Lethality in Oncogenic cells), which is based on the concept of synthetic lethality. This approach aims to create treatments where the inactivation of two specific genes leads to cancer cell death while leaving normal cells unharmed. The company's revenue model will likely be based on the successful development and subsequent licensing or sale of these drug candidates.
Avelos Therapeutics has built a pipeline of four anti-cancer drug candidates. Its leading project, AVS-1001, features the preclinical candidate AD1208, a first-in-class MASTL kinase inhibitor. This oral medication has shown effectiveness in selectively inhibiting cancer cells in lab and animal tests for cancers such as colon, stomach, breast, ovarian, and prostate. Another candidate, AVS-1002, is an inhibitor for a target related to the DNA damage response. The company has secured significant funding to advance these projects, raising a seed round in February 2022, an $8 million Series A in July 2022, and approximately $12.3 million in a Series B round in April 2024, bringing its total funding to around $21.7 million. Avelos Therapeutics presented preclinical findings for its AVS1001 project at the American Association for Cancer Research (AACR) in 2024 and initiated a Phase I clinical trial for AD1208 in December 2024. The company plans to pursue global technology transfers and an eventual listing on the KOSDAQ stock market.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2024 | $12M | $50M | Mirae Asset Venture Investment · LSK Investment · Heungkuk Asset Management · SV Investment | ↗ |
| SERIES A✓Equity / VC | Aug 2022 | $8M | $32M | UTC Investment · SV Investment · QUAD Investment Management · Timefolio Asset Management | ↗ |
Growth signals
Latest recorded traffic for Avelos Therapeutics is 1.1K monthly website visits, down 31.3% over the last three months. Avelos Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Avelos Therapeutics in the Seoul ecosystem
The Avelos Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
UTC Investment
SV Investment- QMQUAD Investment Management
- TMTimefolio Asset Management
Mirae Asset Venture Investment
Mirae Asset Capital- SIStarset Investment
- LILSK Investment
Heungkuk Asset Management- SCShinhan Capital
- TCTimefolio Capital
- QMQuad Asset Management
Medytox Venture Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avelos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avelos Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









